C07C251/12

Process for the preparation of 4-amino-5-fluoro-3-chloro-6-(substituted)picolinates

4-Amino-5-fluoro-3-chloro-6-(substituted)picolinates are prepared from trifluoroacetic acid, p-methoxyaniline, a 3,3-dialkoxyprop-1-yne and a substituted methylene amine by a series of steps.

Process for the preparation of 4-amino-5-fluoro-3-chloro-6-(substituted)picolinates

4-Amino-5-fluoro-3-chloro-6-(substituted)picolinates are prepared from trifluoroacetic acid, p-methoxyaniline, a 3,3-dialkoxyprop-1-yne and a substituted methylene amine by a series of steps.

METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY

Methods of making antidegradant compounds are disclosed in which a p-phenylenediamine is reacted with a dicarbonyl to thereby obtain a diimine, which is reduced to obtain mixtures comprising the antidegradant compound.

METHODS OF MAKING COMPOUNDS AND MIXTURES HAVING ANTIDEGRADANT AND ANTIFATIGUE EFFICACY

Methods of making antidegradant compounds are disclosed in which a p-phenylenediamine is reacted with a dicarbonyl to thereby obtain a diimine, which is reduced to obtain mixtures comprising the antidegradant compound.

Cleavable surfactant

Cleavable surfactants of formula (I) ##STR00001##
having a total hydrophilic-lipophilic balance (HLB) of between 3 and 18 and wherein A is a group capable of releasing a flavor or fragrance aldehyde of formula (R.sup.1)CHO or a flavor or fragrance ketone of formula (R.sup.1)(R.sup.2)CO and is of formula ##STR00002##
wherein the wavy line indicates the location of the bond between L and A; R.sup.1 and R.sup.2 represent a hydrogen atom or a saturated or unsaturated C.sub.1-C.sub.18 hydrocarbon group, provided that at least one of the R.sup.1 or R.sup.2 groups has 6 consecutive carbon atoms and that both R.sup.1 and R.sup.2 taken together comprise a maximum of 18 carbon atoms; and L is a linear, branched or cyclic, saturated or unsaturated C.sub.3 to C.sub.40 hydrocarbon group. These surfactants solubilize and/or stabilize flavor and fragrance aldehydes and ketones in an aqueous environment and at the same time to control their release by hydrolysis.

Cleavable surfactant

Cleavable surfactants of formula (I) ##STR00001##
having a total hydrophilic-lipophilic balance (HLB) of between 3 and 18 and wherein A is a group capable of releasing a flavor or fragrance aldehyde of formula (R.sup.1)CHO or a flavor or fragrance ketone of formula (R.sup.1)(R.sup.2)CO and is of formula ##STR00002##
wherein the wavy line indicates the location of the bond between L and A; R.sup.1 and R.sup.2 represent a hydrogen atom or a saturated or unsaturated C.sub.1-C.sub.18 hydrocarbon group, provided that at least one of the R.sup.1 or R.sup.2 groups has 6 consecutive carbon atoms and that both R.sup.1 and R.sup.2 taken together comprise a maximum of 18 carbon atoms; and L is a linear, branched or cyclic, saturated or unsaturated C.sub.3 to C.sub.40 hydrocarbon group. These surfactants solubilize and/or stabilize flavor and fragrance aldehydes and ketones in an aqueous environment and at the same time to control their release by hydrolysis.

CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
20210085625 · 2021-03-25 ·

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
20210085625 · 2021-03-25 ·

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Controlled release oral pharmaceutical dosage forms comprising MGBG
10881626 · 2021-01-05 · ·

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Controlled release oral pharmaceutical dosage forms comprising MGBG
10881626 · 2021-01-05 · ·

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.